Perspective Therapeutics Inc CATX

Healthcare Biotechnology

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

NYSEAM:CATX - Post by User

Perspective Therapeutics Inc

Bullboard Posts

Comment by kingposton May 24, 2015 3:48pm

156 Views

Post# 23758906

RE:How Jim Cramer and Adam Feursten tricked investors

And #2: They deceived by failing to mention that the others with 97.7 survivability being Chemo and Iodine Seed , we're not a one operation short procedure like ISR ...basically 2 weeks for ISR vs 3 to 5 months for the others with 97.7 %. #3: and lastly they lied outright in conclusion saying the doctor authors of the Peer study found no advantage of the ISR Cesium where in the peer study the author clearly concludes "they recommend ISR cesium.131 seeds for advanced lung cancer".

Bullboard Posts

Day trading vs. swing trading strategies for small-cap stocks